Recifercept

CAS No. 2226238-09-9

Recifercept( —— )

Catalog No. M36832 CAS No. 2226238-09-9

Recifercept (TA-46) is a recombinant human soluble fibroblast growth factor receptor 3, a decoy protein that competes for the ligand of mutant FGFR3.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 816 In Stock
10MG 1302 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Recifercept
  • Note
    Research use only, not for human use.
  • Brief Description
    Recifercept (TA-46) is a recombinant human soluble fibroblast growth factor receptor 3, a decoy protein that competes for the ligand of mutant FGFR3.
  • Description
    Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    FGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2226238-09-9
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Gon?alves D, et al. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368. ?
molnova catalog
related products
  • FIIN-4

    FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.

  • BO-264

    BO-264 is a highly potent and orally active inhibitor of transforming acidic coiled-coil 3 (TACC3, IC50 of 188 nM and a Kd of 1.5 nM).

  • Dovitinib

    A novel, multitargeted RTK inhibitor of class III, IV, and V RTKs.